NYSEAMERICAN:RNN - Rexahn Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.07 0.00 (0.00 %) (As of 05/19/2019 04:00 PM ET)Previous Close$5.07Today's Range$4.99 - $5.0752-Week Range$4.75 - $28.56Volume6,050 shsAverage Volume158,098 shsMarket Capitalization$20.38 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer; and RX-5902 that is in Phase IIa clinical trials to treat patients with metastatic triple negative breast cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. The company has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; Merck Sharp & Dohme B.V.; and BioSense Global LLC. Rexahn Pharmaceuticals, Inc. is headquartered in Rockville, Maryland. Receive RNN News and Ratings via Email Sign-up to receive the latest news and ratings for RNN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:RNN Previous SymbolNYSEMKT:RNN CUSIPN/A CIK1228627 Webrexahn.comcms Phone+1-240-2685300Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees10 Outstanding Shares4,019,000Market Cap$20.38 million Next Earnings Date8/5/2019 (Estimated) OptionableOptionable Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Frequently Asked Questions What is Rexahn Pharmaceuticals' stock symbol? Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "RNN." When did Rexahn Pharmaceuticals' stock split? How did Rexahn Pharmaceuticals' stock split work? Rexahn Pharmaceuticals shares reverse split before market open on Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 11th 2019. An investor that had 100 shares of Rexahn Pharmaceuticals stock prior to the reverse split would have 8 shares after the split. How were Rexahn Pharmaceuticals' earnings last quarter? Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) posted its quarterly earnings results on Monday, May, 13th. The company reported ($0.62) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.93) by $0.31. View Rexahn Pharmaceuticals' Earnings History. When is Rexahn Pharmaceuticals' next earnings date? Rexahn Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Rexahn Pharmaceuticals. What price target have analysts set for RNN? 4 equities research analysts have issued 12-month target prices for Rexahn Pharmaceuticals' stock. Their forecasts range from $23.00 to $96.00. On average, they expect Rexahn Pharmaceuticals' share price to reach $59.50 in the next year. This suggests a possible upside of 1,073.6% from the stock's current price. View Analyst Price Targets for Rexahn Pharmaceuticals. What is the consensus analysts' recommendation for Rexahn Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rexahn Pharmaceuticals in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rexahn Pharmaceuticals. What are Wall Street analysts saying about Rexahn Pharmaceuticals stock? Here are some recent quotes from research analysts about Rexahn Pharmaceuticals stock: 1. According to Zacks Investment Research, "REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. " (5/17/2019) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $10 price target. The majority of contribution to our valuation comes from RX-3117, which represents over 65% of our price target. Remaining valuation comes from RX-5902 (Supinoxin) for triple negative breast cancer. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (3/8/2019) Has Rexahn Pharmaceuticals been receiving favorable news coverage? News headlines about RNN stock have been trending somewhat positive recently, InfoTrie reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rexahn Pharmaceuticals earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. Are investors shorting Rexahn Pharmaceuticals? Rexahn Pharmaceuticals saw a decline in short interest in the month of April. As of April 15th, there was short interest totalling 22,682 shares, a decline of 91.5% from the March 29th total of 266,913 shares. Based on an average daily trading volume, of 58,416 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.6% of the company's shares are short sold. View Rexahn Pharmaceuticals' Current Options Chain. Who are some of Rexahn Pharmaceuticals' key competitors? Some companies that are related to Rexahn Pharmaceuticals include Bionomics (BNO), OptiBiotix Health (OPTI), Tissue Regenix Group (TRX), Orgenesis (ORGS), Promis Neurosciences (PMN), 4d Pharma (DDDD), Noxopharm (NOX), IntelGenx Technologies (IGX), Pediapharm (PDP), Verona Pharma (VRP), Imugene (IMU), Protalix Biotherapeutics (PLX), Ampio Pharmaceuticals (AMPE), Asterias Biotherapeutics (AST) and Immunoprecise Antibodies (IPA). What other stocks do shareholders of Rexahn Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), SLS International (SLS), CytRx (CYTR), CorMedix (CRMD), Madrigal Pharmaceuticals (MDGL), Medallion Financial (MFIN), OncoSec Medical (ONCS), Celsion (CLSN) and Dynavax Technologies (DVAX). Who are Rexahn Pharmaceuticals' key executives? Rexahn Pharmaceuticals' management team includes the folowing people: Dr. Lisa Elizabeth Nolan, Chief Bus. Officer (Age 57)Mr. Douglas J. Swirsky C.F.A., CPA, CPA, CFA, CEO, Pres, CFO, Corp. Sec. & Director (Age 50)Dr. Madhukar H. Trivedi M.D., Consultant Who are Rexahn Pharmaceuticals' major shareholders? Rexahn Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (15.41%), BlackRock Inc. (5.79%), Northern Trust Corp (2.48%), Virtu Financial LLC (0.13%) and Bank of Montreal Can (0.17%). Company insiders that own Rexahn Pharmaceuticals stock include Ben Gil Price, Charles Beever, Douglas J Swirsky and Lisa Nolan. View Institutional Ownership Trends for Rexahn Pharmaceuticals. Which major investors are buying Rexahn Pharmaceuticals stock? RNN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Northern Trust Corp, Virtu Financial LLC and Bank of Montreal Can. Company insiders that have bought Rexahn Pharmaceuticals stock in the last two years include Ben Gil Price, Charles Beever, Douglas J Swirsky and Lisa Nolan. View Insider Buying and Selling for Rexahn Pharmaceuticals. How do I buy shares of Rexahn Pharmaceuticals? Shares of RNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Rexahn Pharmaceuticals' stock price today? One share of RNN stock can currently be purchased for approximately $5.07. How big of a company is Rexahn Pharmaceuticals? Rexahn Pharmaceuticals has a market capitalization of $20.38 million. Rexahn Pharmaceuticals employs 10 workers across the globe. What is Rexahn Pharmaceuticals' official website? The official website for Rexahn Pharmaceuticals is https://rexahn.com/cms/. How can I contact Rexahn Pharmaceuticals? Rexahn Pharmaceuticals' mailing address is 15245 Shady Grove Rd Ste 455, ROCKVILLE, MD 20850-7203, United States. The company can be reached via phone at +1-240-2685300. MarketBeat Community Rating for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 307 (Vote Outperform)Underperform Votes: 248 (Vote Underperform)Total Votes: 555MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe RNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Mutual Funds Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.